Showing results (51-60 of 62) with videos related to
Sort By:
Pageof 7
Journal of Medicinal Chemistry|September 29, 2020
Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic SteatohepatitisJunyou Li, Mengqi Liu, Yazhou Li, et al.European Journal of Medicinal Chemistry|December 28, 2016
Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitorsRangxiao Zhuang, Lixin Gao, Xiaoqing Lv, et al.Journal of Medicinal Chemistry|August 23, 2024
Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological MalignanciesAbdusaid Saidahmatov, Jianan Li, Shihao Xu, et al.Journal of Medicinal Chemistry|June 17, 2024
Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast CancerWen-Jing Wang, Lixin Gao, Simei Wang, et al.Journal of Medicinal Chemistry|September 3, 2021
Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid LeukemiaXu Han, Ning Song, Abdusaid Saidahmatov, et al.Bioorganic & Medicinal Chemistry|October 30, 2025
Discovery of novel 20S proteasome activators for hypoxic cardiomyocyte protection via endoplasmic reticulum stress alleviationDan Wu, Yu Cao, Yubing Han, et al.Bioorganic Chemistry|January 24, 2025
Development of novel epoxyketone macrocyclic peptidyl proteasome inhibitors through OPA-mediated one-step cyclization of unprotected peptidesGongruixue Zeng, Gaoya Xu, Lixin Gao, et al.Bioorganic & Medicinal Chemistry|November 5, 2024
Exploration of novel 20S proteasome activators featuring anthraquinone structures and their application in hypoxic cardiomyocyte protectionQian Yu, Lixin Gao, Linhao Xu, et al.Journal of Medicinal Chemistry|March 28, 2024
Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel DiseaseYuan Li, Tingting Xu, Yue Zhao, et al.Nature|June 10, 2026
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseasesYi Zang, Jingjing Shi, Guanguan Zhao, et al.Pageof 7